A Molecular stratification of chilean gastric cancer patients with potential clinical applicability
Author
dc.contributor.author
Pinto, Mauricio
Author
dc.contributor.author
Córdova Delgado, Miguel
Author
dc.contributor.author
Martínez Retamal, Ignacio
Author
dc.contributor.author
Muñoz Medel, Matías
Author
dc.contributor.author
Bravo, M. Loreto
Author
dc.contributor.author
Duran, Doris
Author
dc.contributor.author
Toledo Villanueva, Francisco Javier
Author
dc.contributor.author
Sánchez, César
Author
dc.contributor.author
Acevedo, Francisco
Author
dc.contributor.author
Mondaca, Sebastián
Author
dc.contributor.author
Koch, Erica
Author
dc.contributor.author
Ibáñez, Carolina
Author
dc.contributor.author
Galindo, Héctor
Author
dc.contributor.author
Madrid, Jorge
Author
dc.contributor.author
Nervi, Bruno
Author
dc.contributor.author
Peña, José
Author
dc.contributor.author
Torres, Javiera
Author
dc.contributor.author
Owen, Gareth I.
Author
dc.contributor.author
Corvalán, Alejandro H.
Author
dc.contributor.author
Armisén, Ricardo
Author
dc.contributor.author
Garrido, Marcelo
Admission date
dc.date.accessioned
2020-10-26T20:11:24Z
Available date
dc.date.available
2020-10-26T20:11:24Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Cancers 2020, 12, 1863
es_ES
Identifier
dc.identifier.other
10.3390/cancers12071863
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/177385
Abstract
dc.description.abstract
Gastric cancer (GC) is a complex and heterogeneous disease. In recent decades, The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) defined GC molecular subtypes. Unfortunately, these systems require high-cost and complex techniques and consequently their impact in the clinic has remained limited. Additionally, most of these studies are based on European, Asian, or North American GC cohorts. Herein, we report a molecular classification of Chilean GC patients into five subtypes, based on immunohistochemical (IHC) and in situ hybridization (ISH) methods. These were Epstein-Barr virus positive (EBV+), mismatch repair-deficient (MMR-D), epithelial to mesenchymal transition (EMT)-like, and accumulated (p53+) or undetected p53 (p53-). Given its lower costs this system has the potential for clinical applicability. Our results confirm relevant molecular alterations previously reported by TCGA and ACRG. We confirm EBV+ and MMR-D patients had the best prognosis and could be candidates for immunotherapy. Conversely, EMT-like displayed the poorest prognosis; our data suggestFGFR2orKRAScould serve as potential actionable targets for these patients. Finally, we propose a low-cost step-by-step stratification system for GC patients. To the best of our knowledge, this is the first Latin American report on a molecular classification for GC. Pending further validation, this stratification system could be implemented into the routine clinic.
es_ES
Patrocinador
dc.description.sponsorship
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDECYT
1180173
1180241
1191928
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
FONDAP-15130011
Takeda Pharmaceutical Company Ltd
P09/016-F
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
21150695
Agency for Science Technology & Research (ASTAR)
CTU06